PRL-8-53
Memory, Verbal Recall
No published human pharmacokinetics. A single small human study from 1978 examined memory effects but did not characterise elimination.
In short
- The entire human evidence base is a single small study published in 1978, and essentially nothing has been published since.
- That study reported improved word recall, with the largest effects in participants over 30 and those with poor baseline recall.
- No pharmacokinetics, no safety database, no replication in nearly fifty years.
- The absence of follow-up over five decades is itself informative — promising results usually attract replication attempts.
- Research compound only, not approved anywhere.
Structure
How it works
PRL-8-53 is a benzoic acid derivative (methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate) synthesised by Nikolaus Hansl at Creighton University in the 1970s.
The proposed mechanism from the original work involves potentiation of dopaminergic and cholinergic transmission, and partial inhibition of serotonin. These descriptions come from the original preclinical characterisation and have not been independently confirmed with modern methods.
There is no contemporary mechanistic work on this compound.
What the research shows
The 1978 study by Hansl enrolled a small number of healthy volunteers in a double-blind crossover design measuring word-list recall. It reported improvement, disproportionately in older participants and in those who performed poorly at baseline.
No replication has been published. No trial has examined any other endpoint, any other population, or any duration of use.
Contemporary reports of effect are anecdotal.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Human — the single 1978 word-recall study | Approximately 0.5 mg/kg as a single dose | oral | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported | 5–20 mg, taken occasionally rather than daily | oral |
No published human pharmacokinetic study establishes a dose, interval, or duration for this compound. Community figures below have no trial behind them and are reports of practice, not evidence. The single study administered one dose to a small group and measured recall hours later. It establishes nothing about repeated use, duration, or safety, and no study since has addressed any of that.
Handling and storage
Oral, as powder or capsules from research-chemical vendors. Sublingual use is described but has no supporting data.
Occasional rather than daily use is the common pattern, reasoned from the single-dose study design rather than from any evidence about repeated administration.
Side effects
No safety database exists. The original study was small and short and would not detect uncommon effects.
Community reports mention headache, and occasionally nausea or irritability.
With no toxicology, no chronic exposure data, and no pharmacokinetics, the honest position is that the safety profile is simply unknown rather than favourable.
Combinations
No interaction data of any kind. The proposed dopaminergic and serotonergic activity would make combination with serotonergic or dopaminergic drugs the theoretically relevant caution, but the mechanism itself is unconfirmed.
Research status
One paper, 1978, by the compound's inventor. That is the complete human literature.
The more useful signal is the silence since: a compound reporting substantial memory enhancement in 1978 that has attracted no replication in almost fifty years is a pattern that usually indicates the result did not hold up, though it can also reflect commercial abandonment.
Legal status
Not approved in any jurisdiction. Not scheduled in most countries, reflecting an absence of assessment rather than a safety finding. Sold for research use only.
WADA status
Not specifically named on the Prohibited List. Falls under WADA class S0, which prohibits any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. Treat it as prohibited in sport.
Conclusion
PRL-8-53 rests on one small study from 1978 conducted by the person who invented it, never replicated.
That is not evidence of nothing — it is evidence of very little, and the enthusiasm it attracts online considerably outstrips what a single unreplicated crossover trial can support.
Sources
- [1]Hansl 1978 — PRL-8-53 effects on verbal recallPubMed
- [2]PRL-8-53 literature searchPubMed
- [3]PubChem CID 70700868PubChem
- [4]WADA Prohibited List (current)WADA
Track your own PRL-8-53 protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.